Page 217 - நாஸ்டாக் உலகளாவிய தேர்ந்தெடுக்கவும் சந்தை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

ERYTECH Completes Enrollment in TRYbeCA-1 Phase 3 Trial in Second-Line Pancreatic Cancer A total of 510 patients enrolled Events required to trigger interim superiority analysis accrued Interim superiority analysis expected in Q1 2021; final analysis in Q4 2021 LYON, France and CAMBRIDGE, Mass., Dec. 14, 2020 (GLOBE NEWSWIRE) ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced the completion of enrollment in the TRYbeCA-1 Phase 3 trial in second-line pancreatic cancer. TRYbeCA-1, the pivotal Phase 3 clinical trial evaluating ERYTECH’s lead product candidate, eryaspase, in second-line metastatic pancreatic cancer, has completed patient enrollment. A total of 510 patients participated in the trial, slightly above the target enrollment of 482 patients.

United statesUnited kingdomFrance generalNew jerseyNicolas merigeauIman el hariryEnregistrement universelPharma bioMathilde bohinCorey davisLouis victor delouvrierJean philippe metgesEric soyerLifesci advisorsCompany securitiesDrug administration